TRS005 / Zhejiang Teruisi Biopharmaceutical - LARVOL DELTA

Safety and Efficacy of TRS005, a Novel Anti-CD20 Antibody-Drug Conjugate, in Patients with Transformed Diffuse Large B-Cell Lymphoma: Results from a Phase I Study (ESMO 2026) - No abstract available

ADC • Clinical • P1 data • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

The anti-CD20 antibody-drug conjugates TRS005 in relapse/refractory CD20-positive B-cell non-Hodgkin lymphoma: A multicenter, open-label, single-arm, phase I study. (ASCO 2024) - P1 | "TRS005 is well-tolerated and exhibits encouraging anti-tumor efficacy in the treatment of R/R DLBCL."

Clinical • P1 data • Diffuse Large B Cell Lymphoma • Hematological Disorders • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

CD20-directed antibody-drug conjugates in non-hodgkin lymphoma: translating preclinical promise into clinical reality. (PubMed, J Hematol Oncol) - "Despite the paradigm-shifting success of anti-CD20 monoclonal antibodies like rituximab, limitations such as antigen loss, impaired host immune effector functions, and resistance remain key challenges in non-Hodgkin lymphoma (NHL). This review provides a focused analysis of clinical- and preclinical-stage CD20-directed ADCs, examining how innovative design strategies-including cleavable linkers, membrane-permeable payloads (e.g., MMAE), site-specific conjugation, and novel platforms such as extracellular drug conjugates (EDCs) and immune-stimulating antibody conjugates (ISACs)-are being developed to circumvent the internalization barrier. We critically analyze clinical progress (MRG001 and TRS005), preclinical innovations, and future directions for translating the promise of CD20-directed ADCs into clinical reality for patients with NHL."

Journal • Preclinical • Review • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

TRS00501001: A Phase 1 Study of TRS005 in Patients With R/R CD20-positive B-NHL. (clinicaltrials.gov) - P1 | N=147 | Active, not recruiting | Sponsor: Zhejiang Teruisi Pharmaceutical Inc. | Recruiting ➔ Active, not recruiting | Trial completion date: Dec 2024 ➔ Dec 2025 | Trial primary completion date: Dec 2023 ➔ Jul 2025

Enrollment closed • Trial completion date • Trial primary completion date • B Cell Non-Hodgkin Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CD20

A Phase I/II Study of TRS005 in Combination With Cyclophosphamide, Doxorubicin, and Prednisone（T-CHP） in Previously Untreated Patients With CD20-positive DLBCL (clinicaltrials.gov) - P1/2 | N=66 | Not yet recruiting | Sponsor: Zhejiang Teruisi Pharmaceutical Inc.

New P1/2 trial • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

A Phase 2 Study of TRS005 in Patients with CD20-positive R/R DLBCL. (clinicaltrials.gov) - P2 | N=139 | Not yet recruiting | Sponsor: Zhejiang Teruisi Pharmaceutical Inc.

New P2 trial • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

A Phase 1 Study of TRS005 in Patients With R/R CD20-positive B-NHL. (clinicaltrials.gov) - P1 | N=152 | Recruiting | Sponsor: Zhejiang Teruisi Pharmaceutical Inc. | Trial completion date: Nov 2022 ➔ Dec 2024 | Trial primary completion date: Aug 2022 ➔ Dec 2023

Trial completion date • Trial primary completion date • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CD20

A phase I study of TRS005: An anti-CD20-MMAE antibody-drug conjugate, in relapsed or refractory b cell non-Hodgkin lymphoma (ESMO 2022) - "ORR/DCR in different histology subtypes : 46.7% and 66.7% in DLBCL (n=15 ), 21.4% and 42.9% in FL (n=14), 100% and 100% in MCL(n=2), 50% and 100% in MZL (n=2). Conclusions TRS005 was well tolerated and showed promising efficacy in pts with relapsed or refractory B-cell NHL who failed standard second-line treatment."

P1 data • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Marginal Zone Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

"CD20+ R/R B-cell NHL | Phase I study of TRS005 (an anti-CD20-MMAE ADC) mPFS 4 months #ESMO22" (,@BaguiasriM)

P1 data • Non-Hodgkin’s Lymphoma • Oncology

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Initial Effectiveness of TRS005 in Patients With Relapsed or Refractory CD20-positive NHL. (clinicaltrials.gov) - P1 | N=121 | Recruiting | Sponsor: Zhejiang Teruisi Pharmaceutical Inc.

New P1 trial • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CD20 • CSF3